Holen Sie sich die Stockscreener-App
234.21
1.38%
-3.27
Handel nachbörslich:
234.21
Schlusskurs vom Vortag:
$237.48
Offen:
$237.15
24-Stunden-Volumen:
947.31K
Relative Volume:
0.87
Marktkapitalisierung:
$38.81B
Einnahmen:
$2.75B
Nettoeinkommen (Verlust:
$714.14M
KGV:
54.09
EPS:
4.33
Netto-Cashflow:
$1.09B
1W Leistung:
-1.08%
1M Leistung:
+5.98%
6M Leistung:
+11.08%
1J Leistung:
+1.09%
1-Tages-Spanne:
$231.60
$238.05
1-Wochen-Bereich:
$231.60
$244.99
52-Wochen-Spanne:
$170.25
$258.93
Veeva Systems Inc Stock (VEEV) Company Profile
Firmenname
Veeva Systems Inc
Sektor
Branche
Telefon
925-452-6500
Adresse
4280 HACIENDA DRIVE, PLEASANTON, CA
Vergleichen Sie VEEV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VEEV
Veeva Systems Inc
|
234.21 | 38.81B | 2.75B | 714.14M | 1.09B | 4.33 |
|
SOLV
Solventum Corp
|
74.75 | 12.84B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
58.51 | 11.36B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
47.83 | 10.16B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
86.96 | 7.54B | 1.15B | 96.70M | -161.99M | 1.09 |
Veeva Systems Inc Stock (VEEV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-23 | Herabstufung | Goldman | Buy → Sell |
| 2024-12-20 | Eingeleitet | Stephens | Overweight |
| 2024-12-04 | Eingeleitet | Mizuho | Outperform |
| 2024-11-19 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-08 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2024-08-27 | Bestätigt | Citigroup | Buy |
| 2024-07-09 | Eingeleitet | BTIG Research | Buy |
| 2023-10-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-10-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-28 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Truist | Buy → Hold |
| 2023-02-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-04 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-06 | Eingeleitet | Cowen | Market Perform |
| 2022-12-02 | Bestätigt | Needham | Buy |
| 2022-10-31 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-10-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | Goldman | Buy |
| 2022-06-21 | Fortgesetzt | Guggenheim | Buy |
| 2022-03-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2022-01-07 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Fortgesetzt | Stifel | Buy |
| 2021-09-02 | Bestätigt | BofA Securities | Buy |
| 2021-09-02 | Bestätigt | JMP Securities | Mkt Outperform |
| 2021-09-02 | Bestätigt | Needham | Buy |
| 2021-09-02 | Bestätigt | UBS | Neutral |
| 2021-07-21 | Eingeleitet | Cowen | Outperform |
| 2021-03-31 | Hochstufung | UBS | Sell → Neutral |
| 2021-01-07 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2020-12-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-10-14 | Fortgesetzt | UBS | Sell |
| 2020-08-28 | Bestätigt | Needham | Buy |
| 2020-07-23 | Eingeleitet | FBN Securities | Outperform |
| 2020-07-07 | Eingeleitet | Stephens | Overweight |
| 2020-06-08 | Eingeleitet | Citigroup | Buy |
| 2020-05-29 | Bestätigt | Needham | Buy |
| 2020-04-13 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-14 | Eingeleitet | Piper Sandler | Overweight |
| 2020-01-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-11-27 | Bestätigt | Canaccord Genuity | Hold |
| 2019-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-08-28 | Bestätigt | Needham | Buy |
| 2019-06-07 | Eingeleitet | Goldman | Neutral |
| 2019-05-30 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2019-05-24 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-27 | Bestätigt | Needham | Buy |
Alle ansehen
Veeva Systems Inc Aktie (VEEV) Neueste Nachrichten
What Does the Market Think About Veeva Systems? - Benzinga
Verve: Embracing Digital-First Quality - Veeva
Exponential Growth Expected for Clinical Data Management - openPR
Veeva Systems, Inc. is hiring: Creative Operations Manager in New York - mediabistro.com
China Expansion Helps Fuel This AI-Powered Cloud Stock In Rough Market - MSN
Electronic Trial Master File (eTMF) Systems Market Size, Trends - openPR
Here's How Much a $1000 Investment in Veeva Systems Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Decentralized Clinical Trials Market to Expand Rapidly Growth - openPR
Raymond James maintains Veeva stock Outperform rating, $285 target - Investing.com
Raymond James maintains Veeva stock Outperform rating, $285 target By Investing.com - Investing.com UK
4 Strategies to Improve Site Engagement | Veeva - Veeva
Decoding Veeva Systems Inc (VEEV): A Strategic SWOT Insight - GuruFocus.com
Cathie Wood's Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen - Benzinga
Veeva Systems Inc. (VEEV) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Automation Meets Flexibility: How Veeva Systems Is Disrupting Pharma Tech With AI & CRM Integration! - Smartkarma
Indero Marks 40th Study Live with Veeva RTSM -March 19, 2025 at 07:04 am EDT - Marketscreener.com
Indero Marks 40th Study Live with Veeva RTSM – Company Announcement - Financial Times
Veeva Systems: Staying Buy Rated As VEEV Is Executing Well (NYSE:VEEV) - Seeking Alpha
Veeva Systems Inc. (VEEV): A Bull Case Theory - MSN
Bayer AG: Harmonizing Data for Impactful Campaigns - Veeva
Clinical Data Management Systems (CDMS) Market Next Big Thing: Major Giants- Oracle, Veeva Systems, Parexel - openPR
Veeva (VEEV) Is Considered a Good Investment by Brokers: Is That True? - Yahoo Finance
Best Momentum Stock to Buy for March 17th - TradingView
Electronic Clinical Outcome Assessment (eCOA) Solution Market - openPR
Here's Why You Should Add Veeva Systems Stock to Your Portfolio Now - MSN
Veeva Shares Advance on Revenue, AI Growth - FX Empire
Veeva Systems (NYSE:VEEV) Announces Tina Hunt's Retirement From Board Before 2025 Shareholders Meeting - Yahoo Finance
Veeva Systems' (NYSE:VEEV) Earnings May Just Be The Starting Point - Simply Wall St
Solid Earnings Reflect Veeva Systems' (NYSE:VEEV) Strength As A Business - Yahoo Finance
Veeva Systems Inc.’s SWOT analysis: cloud software stock faces growth challenges - Investing.com
Veeva Systems announces board member retirement - Investing.com
Veeva Systems announces board member retirement By Investing.com - Investing.com Australia
Veeva Systems Announces Board Member Retirement - TipRanks
Boehringer launches unified platform with Veeva - The Pharma Letter
Top Global Biopharmas Standardize on Veeva China CRM Suite - GuruFocus.com
Veeva Systems Inc (VEEV) Stock Price, Trades & News - GuruFocus.com
Veeva (VEEV) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Boehringer Ingelheim Partners with Veeva to Launch ‘One Medicine Platform’ - Veeva
Boehringer Ingelheim Partners With Veeva To Launch 'One Medicine Platform' -March 11, 2025 at 07:03 am EDT - Marketscreener.com
Boehringer Ingelheim Partners with Veeva to Launch 'One Medicine Platform' - PR Newswire
Veeva Systems Inc. (NYSE:VEEV) Stock Position Decreased by Mutual of America Capital Management LLC - Defense World
Veeva Systems (NYSE:VEEV) Surges 10% After Strong Earnings Report - Yahoo Finance
Scotiabank Forecasts Strong Price Appreciation for Veeva Systems (NYSE:VEEV) Stock - Defense World
Regulatory Information Management Software Market to See Revolutionary Growth: Sparta Systems, Veeva Systems - openPR
Veeva Systems Inc. (NYSE:VEEV) Just Released Its Yearly Earnings: Here's What Analysts Think - Simply Wall St
Robert W. Baird Forecasts Strong Price Appreciation for Veeva Systems (NYSE:VEEV) Stock - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Veeva Systems (NYSE:VEEV) - Defense World
Veeva Systems (NYSE:VEEV) Earns “Overweight” Rating from Stephens - Defense World
Veeva Systems (NYSE:VEEV) Stock Price Expected to Rise, Morgan Stanley Analyst Says - Defense World
Finanzdaten der Veeva Systems Inc-Aktie (VEEV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):